Known targets — ChEMBL curated mechanism
ADRA2AADRA2BADRA2CADRB2AGTR1AVPR1AAVPR1BAVPR2BDKRB2CALCRCHRNA3CHRNB4ESR1ESR2GHSRGNRHRGSC1HSPA8MALT1MC1RMC4RNOS1NOS2NOS3OPRK1OXTRRAMP1RAMP2RAMP3SCN5ASSTR1SSTR2SSTR3SSTR4SSTR5dacAdacBdacCfolPftsImrcAmrcBmrdArplArplBrplCrplDrplErplFrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmFrpmGrpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Acetic Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FFAR3 | O14843 | 1/20 | 0.54 |
| ▸ | LCK | P06239 | 1/20 | 0.54 |
| ▸ | FYN | P06241 | 1/20 | 0.54 |
| ▸ | TSHR | P16473 | 2/20 | 0.46 |
| ▸ | LMNA | P02545 | 2/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.33 |
| ▸ | THPO | P40225 | 1/20 | 0.33 |
| ▸ | CA1 | P00915 | 1/20 | 0.31 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.31 |
| ▸ | BLM | P54132 | 1/20 | 0.31 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Acetic Acid SCHEMBL1704981 | 0.86 | — | — | |
| Acetic Acid SCHEMBL4305539 | 0.80 | — | — | |
| Acetic Acid SCHEMBL1674890 | 0.80 | FFAR3 (0.58) | FFAR3LCKFYNTSHRLMNA | |
| Acetic Acid SCHEMBL19973141 | 0.80 | FFAR3 (0.58) | FFAR3LCKFYNTSHRLMNA | |
| SCHEMBL4871813 | 0.79 | TP53 (0.44) | TSHR | |
| Acetic Acid SCHEMBL9623142 | 0.78 | — | — | |
| Carbamic Acid SCHEMBL9442561 | 0.77 | ACHE (0.54) | TSHRLMNAALOX15BLMPMP22 | |
| Acetic Acid SCHEMBL8865239 | 0.77 | FFAR3 (0.54) | FFAR3LCKFYNTSHRLMNA | |
| Dioxane SCHEMBL29086945 | 0.77 | FFAR3 (0.54) | FFAR3LCKFYNTSHRLMNA | |
| Dioxane SCHEMBL575055 | 0.77 | FFAR3 (0.54) | FFAR3LCKFYNTSHRLMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7417156-B2 | Orally active, antimalarial, anticancer, artemisinin-derived trioxane dimers | JOHNS HOPKINS UNIVERSITY (US) | 2008-08-26 | — | — | US | disclosed |
| US-20060142377-A1 | Orally active, antimalarial, anticancer, artemisinin-derived trioxane dimers with high selectively, stability and efficacy and methods of making the same | JOHNS HOPKINS UNIVERSITY-LICENSE & TECHNOLOGY DEVE (US) | 2006-06-29 | — | — | US | disclosed |
| WO-2004028476-A2 | ARTEMISININ-DERIVED TRIOXANE DIMERS | JOHNS HOPKINS UNIVERSITY (US) | 2004-04-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060142377-A1 | Orally active, antimalarial, anticancer, artemisinin-derived trioxane dimers with high selectively, stability and efficacy and methods of making the same | HCCS, ACIN1, ADH1A | FFAR3 1156/4885LCK 4547/4885FYN 4038/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.